i2-D²EFT: Co-infections and Inflammation in Second-line ART

Phase 4, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by The Kirby Institute. Primary endpoints: Change from baseline in Interleukin-6 level at 48 weeks and Change from baseline of presence/absence of active key co-infections at 48 weeks. Planned start Feb 2021; status: withdrawn.